Related by context. All words. (Click for frequent words.) 68 oral prodrug 67 Azedra 67 lucinactant 67 samarium Sm 66 vapreotide acetate 66 catheter occlusion 66 Xyfid TM 66 FOLOTYN ® 66 CYT# potent vascular disrupting 66 targeted radiotherapeutic 66 dependent kinase inhibitor 66 MAGE A3 ASCI 65 Aztreonam lysine 65 lexidronam injection 65 investigational humanized monoclonal antibody 65 AzaSite Plus 65 liposomal formulation 65 R Saizen R 64 octreotide implant 64 arsenic trioxide injection 64 methylnaltrexone bromide 64 histamine dihydrochloride 64 AAG geldanamycin analog 64 orally administered inhibitor 64 mertansine 64 PDX pralatrexate 64 novel VDA molecule 64 % uracil topical 64 Zorbtive TM 64 Phase III Pivotal 64 IMA# 64 Diabetic Macular Edema DME 64 Phase IIb Trial 64 Hsp# Inhibitor 64 chemotherapy induced neutropenia 64 RNAi therapeutic targeting 64 OMNARIS HFA 64 myelofibrosis polycythemia vera 64 PHASE III 63 non nucleoside HCV 63 novel histone deacetylase 63 JZP 63 TG# [003] 63 sapropterin dihydrochloride 63 sapropterin dihydrochloride Tablets 63 virus HCV protease inhibitor 63 JAK2 Inhibitor 63 LymphoStat B belimumab 63 PNP inhibitor 63 Personalized Immunotherapy 63 Entereg R 63 fluocinolone acetonide 63 prokinetic agent 63 Initiate Clinical Trial 63 acetonide FA 63 refractory chronic lymphocytic 63 Phase Ib clinical trials 63 investigational monoclonal antibody 63 keloid scarring 63 Oracea TM 63 dasatinib Sprycel ® 63 erlotinib Tarceva ® 63 esophageal candidiasis 63 IAP inhibitor 63 tiapamil 63 Bepreve TM 63 oral ridaforolimus 62 Initiate Phase 62 SNT MC# 62 Methylnaltrexone 62 sorafenib tablets 62 Cloretazine 62 ZOLINZA 62 severe hypersensitivity reactions 62 ALN TTR 62 Fibrin Patch 62 Genasense ® oblimersen 62 Exherin TM 62 generation purine nucleoside 62 Pivotal Phase III 62 lintuzumab SGN 62 TKB# 62 alvespimycin 62 product platforms AZX# 62 CIMZIA ™ 62 Lenocta TM 62 non nucleoside inhibitor 62 NAGS deficiency 62 metastatic neuroendocrine tumors 62 sarcoma melanoma 62 Archexin 62 Vidaza azacitidine 62 complement inhibitor eculizumab 62 Intravenous Human 62 Panzem R 62 Prospective Randomized 62 sodium thiosulfate STS 62 IONSYS TM 62 MKC# MKC# PP 62 GAMMAGARD 62 Vicinium TM 62 Fibrillex TM 62 huC# DM4 62 LEP ETU 62 DexaSite 62 Fodosine 62 Tarceva TM 62 Kamada AAT 62 TELCYTA 62 refractory gout 62 ATL/TV# 62 Testosterone MDTS ® 62 CEQ# 61 LHRH antagonists 61 Traficet EN 61 R roscovitine CDK cyclin 61 Aflibercept 61 histone deacetylase HDAC inhibitor 61 Ribavirin causes 61 overactive bladder AA# 61 Cutaneous T 61 AEG# 61 Ophena TM 61 severe oral mucositis 61 Prodarsan R 61 CA4P 61 diabetic macular edema DME 61 Trofex 61 CRMD# 61 VEGFR2 inhibitor 61 intranasal formulation 61 dextromethorphan quinidine 61 torezolid phosphate 61 VA# [002] 61 CINTREDEKIN BESUDOTOX 61 vaginal candidiasis 61 MKC# MT 61 brivaracetam 61 cell lymphoma CTCL 61 Fast Track Status 61 Opterone R 61 apoptosis inducer 61 Anturol TM 61 topically applied SEPA 61 XL# anticancer compounds 61 vaginally administered lidocaine 61 docetaxel Taxotere ® 61 anticancer compound 61 forodesine 61 GTC recombinant human 61 nasal calcitonin product 61 investigational pan BCR 61 R#/MEM # 61 omega interferon 61 candidate XP# 61 lead Aganocide compound 61 Solazed TM 61 Kuvan R 61 TRISENOX ® 61 PROVENGE ® 61 Degarelix 61 ARIKACE 61 diarrhea predominant irritable 61 Lenocta 61 sulodexide 61 severe gastroparesis 61 myelodysplastic myeloproliferative diseases 61 sitaxsentan 61 ospemifene 61 Serostim ® 61 immunocompetent patients 61 DDP# 61 cannabinor 61 CD# monoclonal antibody 61 Vascugel 61 Evoltra ® 61 Elagolix 61 Alocrest 61 Acute Radiation Syndrome ARS 61 treat benign prostatic 60 pralatrexate injection folate analogue 60 somatostatin analogue 60 phase IIb study 60 Resten NG 60 Diabetic Macular Edema 60 MYCAMINE 60 Zenvia ™ 60 Endologix Powerlink System 60 INSPIRE Trial Phase III 60 ALN TTR# 60 radiation sensitizer 60 herpetic keratitis 60 containing granisetron 60 HCV NS5B polymerase 60 treat dysmenorrhea 60 riociguat 60 Safinamide 60 anterior uveitis 60 Phase #b/#a clinical 60 vidofludimus 60 CIMZIA TM certolizumab pegol 60 trastuzumab DM1 T DM1 60 humanized anti 60 Tß4 60 PDE4 inhibitor 60 HuMax EGFr 60 cutaneous T 60 ORENCIA ® 60 selective androgen receptor modulator 60 tumor lysis syndrome 60 Cloretazine ® 60 myeloproliferative diseases 60 human C1 inhibitor 60 PEG PAL 60 Solzira TM 60 pseudobulbar affect PBA 60 TELINTRA 60 Kuvan TM sapropterin 60 Aurexis 60 Known hypersensitivity 60 MAA submission 60 Microplasmin 60 LibiGel ® 60 pain palliation 60 ALN PCS 60 Initiated Phase 60 Cloretazine R VNP#M 60 FDA Approvable Letter 60 postoperative ileus POI 60 Alinia 60 ThermoDox R 60 PEG uricase 60 Golimumab 60 Locteron ® 60 Files IND 60 molecular imaging radiopharmaceutical 60 Silodosin 60 invasive aspergillosis 60 HDAC Inhibitor 60 Onalta 60 EVIZON ™ 60 AeroLEF TM 60 ALVESCO R 60 GTC recombinant form 60 Omacetaxine 60 ACAPODENE 60 PAOD 60 rusalatide acetate 60 ketolide antibiotic 60 HCV protease inhibitor 60 ATPace TM 59 adecatumumab MT# 59 ATL# [001] 59 thetreatment 59 NP2 Enkephalin 59 BrachySil TM 59 SinuNase TM 59 systemic anaplastic large 59 superficial basal cell carcinomas 59 efalizumab 59 MOVIPREP R 59 mu opioid receptor antagonist 59 hoFH 59 Fast Track designations 59 Familial Adenomatous Polyposis FAP 59 Iluvien ® 59 Phase IIa Clinical Trial 59 AzaSite Xtra 59 Catena ® 59 menadione 59 Lupus Nephritis 59 herpes zoster shingles 59 antibody MAb 59 relapsing multiple sclerosis 59 personalized cellular immunotherapy 59 Phase Ib study 59 topical non steroidal 59 Durezol TM 59 GALNS 59 Cannabinor 59 Ozurdex 59 oxypurinol 59 ATL# [002] 59 IL# PE#QQR 59 Staphylococcus aureus Polysaccharide Conjugate 59 Pivotal Trial 59 CD# CEA 59 phase IIb clinical 59 Orphan Drug status 59 PEGylated interferon beta 1a 59 Friedreich Ataxia FRDA 59 Prochymal TM 59 investigational antiplatelet agent 59 BENLYSTA ® 59 ELACYT 59 Phase 1b trial 59 HepaGam B TM 59 fibrotic disease 59 dermal patch 59 NEUMUNE 59 Civacir 59 selective A2A adenosine receptor 59 SinuNase ™ 59 fallopian tube cancers 59 RSD# oral 59 Daclizumab 59 Tasimelteon 59 reslizumab 59 Central Retinal Vein 59 compound PMX # 59 GEM OS2 59 huN# DM1 59 MT# MEDI 59 Arikace 59 RhuDex ® 59 microplasmin 59 treats paroxysmal nocturnal 59 Sezary syndrome 59 DUROS 59 Leber Hereditary Optic Neuropathy 59 leading oral taxane 59 Eculizumab 59 Kit CD# positive 59 acute peripheral arterial 59 Hypotension 59 Nexavar ® 59 granisetron 59 opioid induced bowel dysfunction 59 Toxicities 59 investigational oral hepatitis C 59 Dupuytren Contracture 59 mGluR5 negative 59 Initiates Enrollment 59 quetiapine fumarate 59 Anidulafungin 59 Xcytrin R 59 Panzem 59 bowel syndrome Non 59 INCB# [001] 59 INCB# [003] 59 miconazole Lauriad R 59 ADL# novel 59 Aviptadil 59 MCSP respectively 59 humanized monoclonal antibody 59 Initiates Phase II 59 oral proteasome inhibitor 59 urate lowering 59 VELCADE melphalan 59 Neulasta ® 59 dacetuzumab SGN 59 Cleviprex TM clevidipine 59 BCG refractory carcinoma 59 inhaled iloprost 58 delivers fluocinolone acetonide FA 58 Allovectin 7 R 58 CCR9 antagonist 58 PREOS R 58 unique alkylating agent 58 lumbosacral spine 58 SANVAR 58 OAB overactive bladder 58 gastrointestinal disorders characterized 58 injectable formulation 58 ELND# 58 CB2 selective receptor agonist 58 phase Ib clinical 58 ABL inhibitor 58 mecarbil 58 Sym# 58 topical diclofenac 58 velafermin 58 Phenoptin 58 initiated Phase Ib 58 HoFH 58 secondary hyperparathyroidism 58 Erythropoietic therapies may 58 DuraSite ® 58 Clolar ® 58 Curaxin CBLC# 58 hypercalcemia 58 By JAMAAL ABDUL 58 ZEVALIN ® 58 Cimzia TM 58 Acute Bacterial Sinusitis ABS 58 AZX# 58 cheilitis 58 UPLYSO 58 rALLy clinical trial 58 PRTX 58 IMiDs R 58 PROGENSA R 58 PGL# 58 delayed CINV 58 Oracea ® 58 posaconazole 58 JAK2 inhibitor 58 Pirfenidone 58 invasive candidiasis 58 Phase 1a clinical 58 lymphoid malignancies 58 FASLODEX 58 BROVANA 58 Anturol ® 58 orBec 58 mitogen activated ERK kinase 58 Qutenza TM 58 MEND CABG II 58 ELADUR ™ 58 LymphoStat B TM 58 Lixivaptan 58 include Phenoptin TM 58 GLP1 INT TM 58 PANVAC VF 58 hyperplasia BPH 58 dyskinesia PD LID 58 JAK1 58 gemcitabine Gemzar ® 58 Nanobody 58 acyclovir Lauriad R 58 ruxolitinib 58 PEGINTRON TM 58 hypervascular tumors 58 Orphan Drug designations 58 PI3K/Akt pathway inhibitor 58 XOMA 3AB 58 AZILECT ® 58 IAP inhibitors 58 amifampridine phosphate 58 metformin accumulation 58 Prodarsan ® 58 PrevOnco ™ 58 Octreotide 58 Phase Ib clinical 58 immunomodulatory therapy 58 autologous cellular immunotherapy 58 Pruvel 58 choroidal neovascularization 58 optimal dosing regimens 58 Phase IIa trials 58 oral methylnaltrexone 58 Dalbavancin 58 PSN# [002] 58 ILUVIEN ® 58 CCR5 mAb 58 Phase IIb Clinical Trial 58 topically administered 58 non alcoholic steatohepatitis 58 biologic DMARD 58 Bioral Amphotericin B 58 omacetaxine mepesuccinate 58 Combidex 58 hypereosinophilic syndrome 58 gastrointestinal mucositis 58 PERLANE 58 Phase IIb clinical trials 58 induced macular edema 58 FACTIVE R gemifloxacin 58 postherpetic neuralgia PHN 57 sublingual tablets 57 Spiegelmer ® 57 oxybutynin ATD TM 57 CORT # 57 balsalazide tablet 57 Aclidinium 57 Enkephalin 57 Drug Eluting Stent System 57 Cyclooxygenase Inhibiting Nitric Oxide 57 NanoTab 57 HepeX B TM 57 BUPHENYL 57 arterial thrombosis 57 Aerosurf 57 Fabry Disease 57 intravascular hemolysis 57 AP# [003] 57 RANK Ligand inhibitor 57 ganetespib 57 Guanilib 57 intravitreal injection 57 Acute Ischemic Stroke 57 ALVESCO HFA 57 cytopenias 57 mGluR2 positive 57 NAVISTAR R 57 opioid receptor antagonist 57 Raptiva R 57 hormone LHRH antagonist 57 incyclinide 57 post herpetic neuralgia PHN 57 deferiprone 57 Files Investigational 57 Amphotericin B 57 Benign Prostatic Hyperplasia BPH 57 peritumoral brain edema 57 either acutely decompensated 57 POSIDUR TM 57 Noxafil 57 CINQUIL 57 AQ4N 57 preclinical efficacy 57 SUPPRELIN R LA 57 ongoing Phase 1b 57 investigational compound 57 conjunctival hyperemia 57 hypoxia activated prodrug 57 ORENCIA R 57 Onconase 57 HGS# 57 EVIZON TM 57 alpha interferons 57 LHRH antagonist 57 Phase IIb III 57 Tamibarotene 57 lomitapide 57 PKC# 57 mesylate tablets 57 Apaziquone 57 PROMACTA 57 MOZOBIL 57 SILENOR 57 APTIVUS r 57 multicenter Phase II 57 PXD# 57 Octreolin 57 non constipation irritable 57 nephropathic cystinosis 57 chronic thromboembolic pulmonary 57 drug ISA# 57 MyVax R 57 candidate REP# 57 diabetic neuropathic pain 57 Frova ® 57 ocular allergies 57 Application MAA 57 Application BLA 57 WX UK1 57 registrational 57 OLpur TM H2H 57 Cinryze ™ 57 Maribavir 57 subcutaneous formulation 57 oral nucleoside analogue 57 Emezine 57 BEMA TM Fentanyl 57 ATIR 57 tafamidis 57 AA amyloidosis 57 anti botulism antibody 57 Bone Graft 57 Prestara 57 Inc. AMEX YMI 57 oral antiviral 57 BLA submission 57 lupus renal disease 57 Anavex #-# 57 Factor VIIa 57 GATTEX ® 57 PLK1 SNALP 57 registrational trial 57 Kepivance 57 Pivotal Clinical Trial 57 IIa trial 57 allosteric modulator NAM 57 StaphVAX R 57 small molecule chemotherapeutic 57 Proquin XR 57 ADVANCE PD 57 Onrigin 57 SUTENT ® 57 Abbokinase 57 LEVAQUIN 57 Phase IIIb clinical 57 AA Amyloidosis 57 aflibercept VEGF Trap 57 Anturol 57 INS# [001] 57 Protexia ® 57 constipation OIC 57 highly purified pasteurized 57 MT#/MEDI-# 57 Lupus nephritis 57 FRDA 57 CCR5 antagonist 57 OZURDEX 57 Phase 1a 56 placebo controlled Phase 56 post herpetic neuralgia 56 VALSTAR 56 Ofatumumab 56 TYZEKA 56 plasma kallikrein 56 QNEXA 56 Sanvar R 56 R bendamustine hydrochloride 56 TORISEL 56 posterior uveitis 56 Intravitreal injections 56 pouchitis 56 Zenvia Phase III 56 Exalgo TM 56 REGENERX BIOPHARMACEUTICALS INC. 56 SYCREST 56 Rescula 56 rheumatoid arthritis osteoarthritis ankylosing 56 polyneuropathy HIV DSP 56 cutaneous T cell 56 GLOBE NEWSWIRE Cyclacel Pharmaceuticals 56 Phase Ia 56 Fludara ® 56 apoptosis proteins 56 ThermoDox ® 56 Ceflatonin R 56 memantine HCl 56 ARRY # 56 Zirgan 56 markets Gelclair R 56 Rhucin ® recombinant 56 QTc prolongation 56 BrachySil ™ 56 malignant ascites 56 EP #R 56 Dacogen injection 56 INVEGA ® 56 Aplidin 56 CDAD Clostridium difficile 56 Proxinium TM 56 rFVIIa 56 OncoVEX GM CSF 56 Veronate 56 recurrent glioma 56 MEK inhibitor RDEA# 56 Raptiva ® 56 ARCALYST ® 56 NOXAFIL 56 multicenter Phase III 56 PREOS 56 QuadraSphere 56 intravenous methylnaltrexone 56 verteporfin 56 vaccine GRNVAC1 56 granulated mesalamine 56 candidates Augment ™ 56 refractory acute myeloid 56 Cimzia ® certolizumab pegol 56 cIAI 56 diabetic gastroparesis 56 alvimopan 56 anti CD3 monoclonal 56 Troxatyl 56 SparVax TM 56 Cellegesic 56 NEBIDO R 56 Onalta ™ 56 candidates bavituximab 56 thrombolytic agent 56 ALGRX 56 cytomegalovirus infection 56 symptomatic benign prostatic 56 Phase Ib II 56 SILENOR TM 56 inhaled formulation 56 systemic fungal infections 56 MORAb 56 icatibant 56 investigational HCV polymerase 56 VAPRISOL 56 Voraxaze 56 oral deforolimus 56 Actemra tocilizumab 56 granted Ortec 56 benign prostatic hypertrophy BPH 56 Fast Track Designation 56 Ceflatonin ® 56 Alvesco R 56 Annamycin 56 oxymorphone ER 56 Camvia 56 dose escalation clinical 56 Tavocept 56 TACI Ig 56 Rilonacept 56 Shigamabs ® 56 TMS Therapy 56 Genasense R oblimersen 56 wilate ® 56 Phase 1b clinical 56 iSONEP 56 VQD 56 postsurgical pain 56 eprodisate Fibrillex TM 56 TKM PLK1 56 Onrigin TM 56 immunomodulator 56 heparin induced thrombocytopenia 56 Gabapentin GR 56 faropenem medoxomil 56 Amigal TM 56 Icatibant 56 Critical Limb Ischemia CLI 56 sodium Injection 56 painful diabetic neuropathy 56 post menopausal osteoporosis 56 Hepatocellular Carcinoma HCC 56 Hepatitis C virus HCV 56 Bronchiectasis 56 Soliris eculizumab 56 Oxycyte ® 56 ENTEREG ® 56 pheochromocytoma 56 GORE TAG Device 56 cyclobenzaprine hydrochloride extended 56 intravenous ghrelin agonist 56 dilated cardiomyopathy DCM 56 Relapsing Remitting Multiple Sclerosis 56 PresbyLens ® 56 liver resection surgeries 56 Parkinson disease levodopa induced 56 atherothrombotic events 56 GLP toxicology studies 56 actinic keratosis AK 56 acute GvHD 56 homozygous familial hypercholesterolemia 56 TBC# 56 squalamine 56 phase IIa clinical 56 dose escalation Phase 56 venous stasis ulcers 56 CORLUX CORT # 56 PHX# 56 recurrent malignant glioma 56 phase Ib 56 TH# [003] 56 serotonergic drugs 56 Tectin TM 56 NEBIDO 56 ARIXTRA 55 LEUKINE 55 hereditary deficiency 55 zolpidem tartrate sublingual tablet 55 MGCD# [001] 55 MEK inhibitor 55 schizophrenia CIAS 55 Aggrastat ® tirofiban hydrochloride 55 IND submission 55 TASKi3 55 Protectan CBLB# 55 PrevOnco 55 EVIZON 55 occlusion CRVO 55 Glybera 55 ApoB SNALP 55 multicenter Phase 55 SparVax ™ 55 Biological License Application 55 STEDESA 55 JAK inhibitor 55 DOS# 55 Diamyd ® 55 Zavesca ® 55 LUMINATE 55 ONCONASE 55 Bendamustine 55 Phase IIa trial 55 non metastatic osteosarcoma 55 relapsed refractory multiple myeloma 55 relapsing remitting MS RRMS 55 anticancer agent 55 hylan GF 55 Angioedema 55 Somatuline R Autogel R 55 blepharitis 55 Topical Interferon Alpha 2b 55 Zelrix 55 Targretin capsules 55 Levulan PDT 55 paroxysmal nocturnal hemoglobinuria 55 pathologic myopia 55 MULTAQ 55 recurrent herpes labialis 55 topical anti infective 55 RAPTIVA 55 Phase 2a clinical 55 ST Elevation Myocardial 55 Prodarsan 55 Dupuytren Disease 55 pericardial effusion 55 vitreous hemorrhage 55 hypopigmentation 55 Ceflatonin 55 Ketotransdel 55 eniluracil 55 Injectable Bone Graft 55 Tolvaptan 55 Laquinimod 55 Allovectin 7 55 castrate resistant prostate cancer 55 QLT# 55 SomatoKine 55 NeutroSpec 55 PRISTIQ 55 lenalidomide Revlimid R 55 Occlusive Disease 55 Nasdaq DVAX 55 Augment TM 55 VitiGam 55 glucocorticoid induced osteoporosis 55 Phase IIb trials 55 palifosfamide 55 EOquin 55 dysplastic lesions 55 Firazyr 55 EVIZON TM squalamine lactate 55 Perceiva 55 ruboxistaurin 55 ABILIFY ® 55 PRNewswire FirstCall Genta Incorporated 55 Tekamlo 55 choroidal neovascularization CNV 55 Entereg TM 55 Pharmos pipeline 55 postoperative ileus 55 Abiraterone acetate 55 TYKERB 55 candidemia 55 Indaflex TM 55 Soft Tissue Sarcoma 55 CellCept mycophenolate mofetil 55 catheter occlusion CO 55 phase IIa 55 ATryn ® GTC recombinant 55 ZYVOX 55 Clevudine 55 IMiDs 55 KNS # 55 tumor necrosis 55 hematologic disorders 55 Phase 2a 55 blinded randomized placebo controlled 55 sJIA 55 neovascular diseases 55 AGHD 55 Phase IIB 55 opioid analgesia 55 Protexia R 55 chronic idiopathic thrombocytopenic purpura 55 OMAPRO ™ 55 P#X# antagonist 55 severe hypercholesterolemia 55 idiopathic thrombocytopenic purpura ITP 55 CIP TRAMADOL ER 55 TKM ApoB 55 carcinoid syndrome 55 elevated intraocular pressure 55 atypical hemolytic uremic syndrome 55 teduglutide 55 ONTAK 55 Glypromate 55 cetrorelix pamoate 55 cytopenia 54 enzastaurin 54 post surgical adhesions 54 ORE# 54 Aryplase 54 neovascular 54 adrenal suppression 54 Junovan 54 octreotide 54 BEMA Buprenorphine 54 uvea 54 tezampanel NGX# 54 TRANSDUR Sufentanil 54 Lauriad 54 Infusion Reactions Severe 54 Inc. Nasdaq CYCC 54 HeFH 54 Linaclotide 54 herpes labialis 54 noninfectious uveitis 54 Fx #A 54 Submits Investigational 54 SomatoKine R 54 heterozygous FH 54 candidate NGX 54 randomized Phase IIb 54 generation URAT1 inhibitor 54 post operative ileus 54 eltrombopag 54 dextofisopam 54 investigational hepatitis B 54 Invasive fungal infections 54 QNEXA ® 54 Curaxin 54 terlipressin 54 next generation URAT1 54 POSIDUR TM ELADUR TM 54 lymphoma CTCL 54 inhaled liposomal ciprofloxacin 54 Systemic lupus erythematosus SLE 54 Zenvia TM 54 gastroduodenal 54 sBLA 54 Retisert 54 Neovascular AMD 54 SonoLysis 54 initiate Phase IIa 54 Pulmonary Embolism PE 54 Phase 1b 54 DACH platinum 54 serologically active systemic lupus 54 thyrotoxicosis 54 Fibrin Pad 54 compound INCB# 54 gout flares 54 Augment Injectable 54 O PPDS 54 CVBT #B 54 Junovan TM 54 investigational hepatitis C 54 BLA filing 54 SPRIX ® 54 Hypoactive Sexual Desire Disorder 54 Acute Myeloid Leukemia AML 54 Genasense ® 54 CG# [003] 54 forodesine HCl 54 VEGF Trap 54 pegaptanib 54 retinal vein occlusion 54 Celacade TM technology 54 rhIGF-I/rhIGFBP-3 54 LEVADEX TM 54 TM Drug Eluting 54 Host Disease GvHD 54 cinacalcet HCl 54 hyperammonemia 54 hypomagnesemia 54 RenaZorb TM 54 Phase 2a clinical trials 54 novel orally administered 54 Alphanate R 54 Deferiprone 54 motexafin gadolinium Injection 54 antiarrhythmic drug 54 VIIBRYD 54 PENNSAID 54 Phase Ib 54 Tarvacin TM 54 metastatic malignant melanoma 54 synthetic retinoid 54 Cotara R 54 relapsed multiple myeloma 54 REMOXY R 54 tramiprosate 54 acute coronary syndromes ACS 54 L PPDS 54 TRANSDUR TM Sufentanil 54 photocoagulation 54 dose escalation trial 54 Nerve Targeting Drug 54 Ventavis 54 Cinryze TM 54 Certolizumab pegol 54 ABRAXANE ® 54 pharmacological chaperone 54 potently inhibit 54 Phase 2b study 54 RIGScan ™ 54 initiate Phase 1b 54 FROVA 54 Nasdaq PGNX today 54 haematologic 54 rALLy 54 Telavancin 54 Nasdaq VNDA 54 Orphan Drug Status 54 refractory angina 54 Peyronie Disease 54 confirmatory Phase III 53 tamponade 53 rectovaginal fistulas 53 candidiasis 53 Soliris TM eculizumab 53 Manja Bouman CEO 53 cutaneous lupus 53 opioid induced constipation OIC 53 Biologics License Application BLA 53 nosocomial pneumonia 53 Increlex TM 53 tardive dyskinesia TD 53 Marqibo 53 thrombin component 53 fungoides 53 Orathecin 53 ofatumumab HuMax CD# 53 KIACTA ™ 53 tamibarotene 53 Aurora kinase inhibitor 53 refractory Hodgkin lymphoma